This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
Animals can be inaccurate testing models for human treatments, especially for disease states involving a human immune response, such as in cancer. 4 Testing also causes stress on the animals, leading to increased immune or biological responses and confounding disease data outcomes.
Furthermore, delays in medication access can exacerbate chronic conditions, such as diabetes, hypertension, and asthma, leading to increased hospitalization rates. Patients may be unable to obtain critical medications, resulting in poor adherence and negative outcomes.
Related Videos Related Content Advertisement June 27th 2025 Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP Luke Halpern, Assistant Editor June 3rd 2025 S2.
Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. Systemic inequities, misinformation, and geographic disparities hindered vaccination efforts, with significant coverage gaps among racial and rural populations.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
4 Novak added that these services align well with appointment-based models and can be layered with immunizations, chronic disease monitoring, and medication therapy management. Addressing Barriers and Finding Solutions Despite the promise of these services, challenges remain.
The study aimed to evaluate both safety and preliminary efficacy outcomes, with a specific focus on hematologic toxicity, pharmacokinetics, and immune system effects. Patients were trained to self-administer their infusion at home or attend clinic visits 3 times weekly.
During the session “Collaborative Practice, Statewide Protocols, and Independent Prescriptive Authority: How Pharmacy is Expanding Services to Increase Access to Patients,” Klepser highlighted the importance of moving beyond product dispensing to provide higher-level services, such as immunizations and medication therapy management.
link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
Yet, despite growing awareness, HFpEF remains difficult to manage due to nonspecific symptoms, limited clinical trial data, and inconsistencies in diagnosis. As several pharmacists explained, the challenge often begins with identifying who has HFpEF.
Receiving CAR T therapy can take several weeks, and though very effective against difficult-to-treat cancers, it can sometimes cause life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
SHOW MORE Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake. Pediatric vaccination laws vary, but pharmacists play a crucial role in educating families about vaccines like MMR, Tdap, and HPV. Before autumn approaches, start thinking about respiratory vaccines.
link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
Finerenone and the Future of Diabetes-Related Kidney Care Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content